Renal protective effect in hypertensive patients: The high doses of angiotensin II receptor blocker (HARB) study

Hypertension Research

Volumn 30, Issue 12, 2007, Pages 1187-1192

  Ohishi, Mitsuru ^a   Takagi, Takashi ^a   Ito, Takashi ^a   Tatara, Yuji ^a   Hayashi, Norihiro ^a   Shiota, Atsushi ^a   Iwamoto, Yoshihiro ^a   Katsuya, Tomohiro ^a   Rakugi, Hiromi ^a   Ogihara, Toshio ^a  

^a OSAKA UNIVERSITY GRADUATE SCHOOL OF MEDICINE   (Japan)

Author keywords

Changeover; High dosage; Japanse Society of Hypertension Guidelines for the Management of Hypertension (JSH 2004); Urinary protein excretion; Valsartan

Indexed keywords

ALPHA ADRENERGIC RECEPTOR BLOCKING AGENT; ANGIOTENSIN RECEPTOR ANTAGONIST; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; CALCIUM CHANNEL BLOCKING AGENT; CANDESARTAN; CREATININE; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; DIURETIC AGENT; VALSARTAN;

ADULT; AGED; ARTICLE; BLOOD PRESSURE MEASUREMENT; CONTROLLED STUDY; CORRELATION ANALYSIS; CREATININE URINE LEVEL; DIASTOLIC BLOOD PRESSURE; DOSE RESPONSE; DRUG MEGADOSE; DRUG SUBSTITUTION; DRUG WITHDRAWAL; FEMALE; GLOMERULUS FILTRATION RATE; HUMAN; HYPERTENSION; JAPAN; MAJOR CLINICAL STUDY; MALE; PROTEIN URINE LEVEL; PROTEINURIA; PULSE RATE; RENAL PROTECTION; SYSTOLIC BLOOD PRESSURE; TREATMENT OUTCOME; URINARY EXCRETION;

AGED; ANGIOTENSIN II TYPE 1 RECEPTOR BLOCKERS; ANTIHYPERTENSIVE AGENTS; BENZIMIDAZOLES; BLOOD PRESSURE; DOSE-RESPONSE RELATIONSHIP, DRUG; FEMALE; HEART RATE; HUMANS; HYPERTENSION; KIDNEY; MALE; MIDDLE AGED; PROTEINURIA; TETRAZOLES; VALINE;

EID: 38749118312     PISSN: 09169636     EISSN: 13484214     Source Type: Journal    
DOI: 10.1291/hypres.30.1187     Document Type: Article

References (25)

1. Peralta CA, Kurella M, Lo JC, Chertow GM: The metabolic syndrome and chronic kidney disease. Curr Opin Nephrol Hypertens 2006; 15: 361-365.
2. Segura J, Campo C, Gil P, et al: Development of chronic kidney disease and cardiovascular prognosis in essential hypertensive patients. J Am Soc Nephrol 2004; 15: 1616-1622.
3. De Leeuw PW, Thijs L, Birkenhager WH, et al: Prognostic significance of renal function in elderly patients with isolated systolic hypertension: results from the Syst-Eur trial. J Am Soc Nephrol 2002; 13: 2213-2222.
4. Marin R, Gorostidi M, Fernandez-Vega F, Alvarez-Navascues R: Systemic and glomerular hypertension and progression of chronic renal disease: the dilemma of nephrosclerosis. Kidney Int Suppl 2005; (99): S52-S56.
5. 2+ channels in renal microcirculation. J Pharmacol Sci 2005; 99: 221-227.
6. Wang T, Takabatake T: Effects of vasopeptidase inhibition on renal function and tubuloglomerular feedback in spontaneously hypertensive rats. Hypertens Res 2005; 28: 611-618.
7. Caldicott WJ, Taub KJ, Margulies SS, Hollenberg NK: Angiotensin receptors in glomeruli differ from those in renal arterioles. Kidney Int 1981; 19: 687-693.
8. Brenner BM, Cooper ME, de Zeeuw D, et al: Effects of losartan on renal and cardiovascular outcomes in patients with type 2 diabetes and nephropathy. N Engl J Med 2001; 345: 861-869.
9. Ruggenenti P, Perna A, Loriga G, et al: Blood-pressure control for renoprotection in patients with non-diabetic chronic renal disease (REIN-2): multicentre, randomised controlled trial. Lancet 2005; 365: 939-946.
10. Julius S, Kjeldsen SE, Weber M, et al: Outcomes in hypertensive patients at high cardiovascular risk treated with regimens based on valsartan or amlodipine: the VALUE randomised trial. Lancet 2004; 363: 2022-2031.
11. Parving HH, Lehnert H, Brochner-Mortensen J, et al: The effect of irbesartan on the development of diabetic nephropathy in patients with type 2 diabetes. N Engl J Med 2001; 345: 870-878.
12. Fujikawa K, Hasebe N, Kikuchi K: Cost-effectiveness analysis of hypertension treatment: controlled release nifedipine and candesartan low-dose combination therapy in patients with essential hypertension - the Nifedipine and Candesartan Combination (NICE-Combi) Study. Hypertens Res 2005; 28: 585-591.
13. Pfeffer MA, Swedberg K, Granger CB, et al: Effects of candesartan on mortality and morbidity in patients with chronic heart failure: the CHARM-Overall programme, Lancet 2003; 362: 759-766.
14. Cohn JN, Tognoni G: A randomized trial of the angiotensin-receptor blocker valsartan in chronic heart failure. N Engl J Med 2001; 345: 1667-1675.
15. Pfeffer MA, McMurray JJ, Velazquez EJ, et al: Valsartan, captopril, or both in myocardial infarction complicated by heart failure, left ventricular dysfunction, or both. N Engl J Med 2003; 349: 1893-1906.
16. Imai E, Horio M, Nitta K, et al: Estimation of glomerular filtration rate by the MDRD study equation modified for Japanese patients with chronic kidney disease. Clin Exp Nephrol 2007; 11: 41-50.
17. Fogari R, Mugellini A, Zoppi A, et al: A double-blind crossover study of the antihypertensive efficacy of angiotensin II-receptor antagonists and their activationof the renin-angiotensin system. Curr Ther Res Clin Exp 2000; 61: 669-679.
18. Guidelines Committee: 2003 European Society of Hypertension-European Society of Cardiology guidelines for the management of arterial hypertension. J Hypertens 2003; 21: 1011-1053.
19. Chobanian AV, Bakris GL, Black HR, et al: The Seventh Report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure: the JNC 7 report. JAMA 2003; 289: 2560-2572.
20. The ALLHAT Officers and Coordinators for the ALLHAT Collaborative Research Group: Major outcomes in high-risk hypertensive patients randomized to angiotensin-converting enzyme inhibitor or calcium channel blocker vs diuretic: the Antibypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT). JAMA 2002; 288: 2981-2997.
21. Peterson JC, Adler S, Burkart JM, et al: Blood pressure control, proteinuria, and the progression of renal disease. The Modification of Diet in Renal Disease Study. Ann Intern Med 1995; 123: 754-762.
22. Weinberg M, Weinberg A, Cord R, Zappe D: The effect of high-dose angiotensin II receptor blockade beyond maximal recommended doses in reducing urinary protein excretion. JRAAS 2001; 2: S196-S198.
23. Hollenberg NK, Parving HH, Viberti G, Remuzzi G: The Diovan Reduction of Proteinuiria (DROP) Study: albuminuria response to high-doses of valsartan in type 2 diabetes mellitus. Circulation 2006; 114: II-61.
24. Lithell H, Hansson L, Skoog I, et al: The Study on Cognition and Prognosis in the Elderly (SCOPE): principal results of a randomized double-blind intervention trial. J Hypertens 2003; 21: 875-886.
25. Suzuki H, Kanno Y: Effects of candesartan on cardiovascular outcomes in Japanese hypertensive patients. Hypertens Res 2005; 28: 307-314.